← 返回

重编程肿瘤微环境中抑制 T 细胞的细胞因子图谱:精准抗癌治疗的新前沿

英文原题:Rewiring the T cell-suppressive cytokine landscape of the tumor microenvironment: a new frontier for precision anti-cancer therapy.

查看英文原题

Rewiring the T cell-suppressive cytokine landscape of the tumor microenvironment: a new frontier for precision anti-cancer therapy.

PubMed 2024/08/30(内容时间) Front Immunol Q1 · IF 7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

浸润肿瘤微环境(TME)的T淋巴细胞往往无法作为有效的抗癌因子发挥作用。在TME中,细胞间的抑制性相互作用在削弱其抗肿瘤活性方面发挥重要作用。近年来的研究揭示,TME中由免疫细胞和非免疫细胞以及肿瘤细胞本身释放的可溶性因子,有助于加剧T细胞耗竭。我们对TME细胞因子图谱、它们之间的相互关系及其对癌症发展影响的理解仍处于早期阶段。在这篇综述中,我们旨在阐明Interleukin(IL)-6、IL-9和IL-10——这一小群在TME中具有T细胞抑制效应的JAK/STAT信号依赖性细胞因子——并总结其作用机制。此外,我们将探讨科学研究的进步如何帮助我们克服肿瘤中抑制T细胞的细胞因子所带来的障碍,最终目标是促进进一步研究,以开发新型治疗策略来对抗其促肿瘤活性。

展开英文摘要原文

T lymphocytes that infiltrate the tumor microenvironment (TME) often fail to function as effective anti-cancer agents. Within the TME, cell-to-cell inhibitory interactions play significant roles in dampening their anti-tumor activities. Recent studies have revealed that soluble factors released in the TME by immune and non-immune cells, as well as by tumor cells themselves, contribute to the exacerbation of T cell exhaustion.

Our understanding of the cytokine landscape of the TME, their interrelationships, and their impact on cancer development is still at its early stages. In this review, we aim to shed light on Interleukin (IL) -6, IL-9, and IL-10, a small group of JAK/STAT signaling-dependent cytokines harboring T cell-suppressive effects in the TME and summarize their mechanisms of action.

Additionally, we will explore how advancements in scientific research can help us overcoming the obstacles posed by cytokines that suppress T cells in tumors, with the ultimate objective of stimulating further investigations for the development of novel therapeutic strategies to counteract their tumor-promoting activities.

论文信息

作者
Lopresti L、Tatangelo V、Baldari CT、Patrussi L
单位
Department of Life Sciences, University of Siena, Siena, Italy.Italy
文献类型
综述 · 非美国政府资助研究
期刊
Frontiers in immunology2024
原文标识
PubMed 39281678 · DOI 10.3389/fimmu.2024.1418527